Solid biosciences provides update regarding sgt-001 phase i/ii clinical hold on ignite dmd

Cambridge, mass., may 07, 2020 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy, announced that it received written communication from the u.s. food and drug administration (fda) regarding the clinical hold placed on the company’s ignite dmd phase i/ii clinical trial. the program remains on clinical hold and the company will continue to work with the fda to address their requests. 
SLDB Ratings Summary
SLDB Quant Ranking